Table 1.
Baseline characteristics.
| Platinum-Based Chemotherapy Backbone N = 229 | Non-Platinum Chemotherapy Doublet Backbone N = 223 | |
|---|---|---|
| Age (years) | Median 46 (range, 20–85) | median 48 (range, 22–82) |
| Histology | ||
| Squamous | 71% | 65% |
| Adenocarcinoma | 19% | 19% |
| Adenosquamous | 9% | 10% |
| Other | 0% | 5% |
| Race | ||
| White | 78% | 77% |
| Black | 13% | 13% |
| Asian | 5% | 4% |
| Pacific Islander | 0.4% | 0.0% |
| Other | 3% | 6% |
| Disease status | ||
| Recurrent | 75% | 69% |
| Persistent | 9% | 14% |
| Metastatic | 16% | 17% |
| GOG performance status | ||
| 0 | 57% | 59% |
| 1 | 43% | 41% |
| Previous platinum-based radiosensitizing chemotherapy | 76% | 74% |
| Pelvic disease | 50% | 57% |
| Prior radiation therapy | 80% | 79% |
| Target lesion in radiation field | ||
| Yes | 39% | 40% |
| No | 60% | 59% |
| Unknown | 1% | 0% |